CN113318174B - Children ginseng-radix astragali-poria cocos particle as well as preparation method and application thereof - Google Patents

Children ginseng-radix astragali-poria cocos particle as well as preparation method and application thereof Download PDF

Info

Publication number
CN113318174B
CN113318174B CN202110803847.3A CN202110803847A CN113318174B CN 113318174 B CN113318174 B CN 113318174B CN 202110803847 A CN202110803847 A CN 202110803847A CN 113318174 B CN113318174 B CN 113318174B
Authority
CN
China
Prior art keywords
parts
poria cocos
ginseng
preparation
root
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110803847.3A
Other languages
Chinese (zh)
Other versions
CN113318174A (en
Inventor
张环宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jilin Huanyu Jimin Technology Co ltd
Original Assignee
Jilin Huanyu Jimin Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jilin Huanyu Jimin Pharmaceutical Co ltd filed Critical Jilin Huanyu Jimin Pharmaceutical Co ltd
Priority to CN202110803847.3A priority Critical patent/CN113318174B/en
Publication of CN113318174A publication Critical patent/CN113318174A/en
Application granted granted Critical
Publication of CN113318174B publication Critical patent/CN113318174B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/34Campanulaceae (Bellflower family)
    • A61K36/344Codonopsis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • A61K36/07Basidiomycota, e.g. Cryptococcus
    • A61K36/076Poria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/57Magnoliaceae (Magnolia family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/65Paeoniaceae (Peony family), e.g. Chinese peony
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/69Polygalaceae (Milkwort family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/79Schisandraceae (Schisandra family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/80Scrophulariaceae (Figwort family)
    • A61K36/804Rehmannia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/81Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815Lycium (desert-thorn)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/888Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/894Dioscoreaceae (Yam family)
    • A61K36/8945Dioscorea, e.g. yam, Chinese yam or water yam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/39Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50Methods involving additional extraction steps
    • A61K2236/51Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a pediatric ginseng-astragalus-poria cocos particle for treating attention deficit hyperactivity disorder and a preparation method and application thereof. Treat both manifestation and root cause of disease and improve various symptoms. The traditional Chinese medicine composition has been used clinically for years, and the effective rate of patients with symptom improvement can reach more than 95 percent. The preparation has definite curative effect, no adverse reaction and good safety.

Description

Children ginseng-radix astragali-poria cocos particle as well as preparation method and application thereof
Technical Field
The invention relates to the field of traditional Chinese medicine compound research, in particular to a pediatric ginseng-radix astragali-poria cocos particle for treating attention deficit hyperactivity disorder and a preparation method and application thereof.
Background
ADHD (Attention-deficit hyperactivity disorder), a common mental disorder in childhood. This condition is called "hyperactive Disorder" (Hyperkinetic Disorder) according to the world health organization's handbook of general disease classifications, tenth edition (ICD-10, WHO, 1992).
For the treatment of ADHD, the record of Xiaoyao san is recorded in Shang Han Lun in traditional Chinese medicine as early as possible. After long-term practice, the later-aged doctors accumulate abundant clinical experience. The modern Chinese medicine students find that the main syndrome differentiation and classification of the hyperactivity of children are 'kidney yin deficiency, liver yang hyperactivity', 'heart and kidney qi deficiency' and 'disharmony between heart and kidney'. The syndrome of water-fire loss, the syndrome of deficiency of both heart-qi and yin, the syndrome of deficiency of heart-spleen qi, the syndrome of disturbance of heart-fire by phlegm-fire, the syndrome of hyperactivity of heart-liver-fire, the syndrome of disturbance of heart-liver-kidney, the syndrome of insufficiency of spleen-qi, the syndrome of internal stagnation of phlegm, the syndrome of disharmony of liver and spleen, the syndrome of liver-depression and spleen-deficiency, the syndrome of internal stagnation of blood stasis and the like, the syndrome with the largest clinical proportion is the syndrome of spleen-deficiency and kidney-yin and liver-yang hyperactivity. Accounting for more than one third of the sum of syndrome types.
The theory of traditional Chinese medicine considers that the brain is the house of "Jingming", the spiritual memorability is in the brain ", also the house of spirit, the spirit governing the five internal organs, so the attention, learning ability, memory and intelligence are closely related to the function of the brain. The brain is the marrow sea, the development and the function of the brain are closely related to the profit and the loss of the marrow sea, the sufficiency of the marrow sea directly influences the function of the brain, the marrow is sufficient, the brain is vigorous, and the response is sensitive; empty marrow is a cause of disharmony and poor memory. The marrow is originated from the kidney, the kidney stores essence, and governs bone to produce marrow and is led to the brain, and the mind and geisha are both in the kidney and the zang-fu organs are diseased together. From the differentiation of syndromes of five zang organs, the zang-fu organs are mainly related to the spleen, kidney, liver and heart. The most prominent zang-fu organs are the spleen and the liver, and they are the syndrome of common diseases of both organs. From the differentiation of syndromes of deficiency and excess, the most common syndrome is the syndrome of mixed deficiency and excess caused by excess and deficiency, the syndrome of kidney deficiency is more obvious in each type, the syndrome differentiation of five zang organs is mainly based on kidney, the three types of spleen and kidney, liver and kidney and heart and kidney may belong to the parallel syndrome type in kidney syndrome differentiation, the three types all have the common characteristics of kidney deficiency, the difference is that the difference of the other common disease is the spleen, heart and liver, and the three types of compound syndromes are greatly different in the aspects of etiology origin, syndrome manifestation and development change. At present, no traditional Chinese medicine capable of effectively treating attention deficit hyperactivity disorder exists, and the following technical scheme is provided in the application in order to solve the problems existing at present.
Disclosure of Invention
The invention aims to provide the children ginseng-astragalus root and poria cocos particle for treating attention deficit hyperactivity disorder, breaks through the traditional treatment thought of tonifying liver and kidney, has the effects of tonifying qi and spleen, nourishing yin and suppressing hyperactive yang, and supporting intelligence and calming heart, and is mainly used for traditional Chinese medicine differentiation of attention deficit hyperactivity disorder, namely qi-yin deficiency and yin-deficiency and yang-excess. The symptoms are as follows: restlessness, distraction, urgency, irritability, multilingual, night sweats, dry mouth and tongue, feverish palms and soles. The preparation has definite curative effect, no adverse reaction and good safety.
In order to achieve the above purpose, the invention provides the following technical scheme:
the invention firstly provides attention deficit hyperactivity disorder-treating children ginseng-astragalus root poria cocos granules, which are prepared from the following raw material medicines in parts by weight: 15-25 parts of codonopsis pilosula, 15-25 parts of prepared rehmannia root, 10-20 parts of white peony root, 8-12 parts of schisandra chinensis, 10-20 parts of Chinese yam, 8-12 parts of polygala tenuifolia, 10-20 parts of keel, 8-12 parts of wolfberry fruit, 10-20 parts of rhizoma acori graminei and 10-20 parts of poria with hostwood.
Preferably, the pediatric ginseng, radix astragali, poria cocos and poria cocos granules are prepared from the following raw material medicines in parts by weight: 3 parts of codonopsis pilosula, 3 parts of prepared rehmannia root, 3 parts of white peony root, 2 parts of schisandra chinensis, 3 parts of Chinese yam, 2 parts of polygala tenuifolia, 3 parts of keel, 2 parts of wolfberry fruit, 3 parts of rhizoma acori graminei and 3 parts of poria with hostwood.
Preferably, the pediatric ginseng, radix astragali, poria cocos and poria cocos granules are prepared from the following raw material medicines in parts by weight: 5 parts of codonopsis pilosula, 5 parts of prepared rehmannia root, 3 parts of white peony root, 2 parts of schisandra chinensis, 3 parts of Chinese yam, 2 parts of polygala tenuifolia, 3 parts of keel, 2 parts of wolfberry fruit, 3 parts of rhizoma acori graminei and 3 parts of poria with hostwood.
In the formula, the codonopsis pilosula has the effects of tonifying qi and spleen, and the prepared rehmannia root has the effects of nourishing yin and blood, and the codonopsis pilosula and the rehmannia root are monarch drugs, so that the kidney is benefited and the essence is filled, the marrow is generated, the brain is supplemented, the spirit is condensed, the attention is enhanced, and the cognitive function is improved, so that the treatment effect is achieved; the white peony root has the functions of nourishing liver and kidney, nourishing blood and tonifying heart, the Chinese magnoliavine fruit has the functions of tonifying kidney and calming heart, and the Chinese yam has the functions of nourishing kidney and replenishing vital essence, and tonifying qi and strengthening spleen as ministerial drugs; cortex et radix Polygalae has effects of tranquilizing mind and improving intelligence, Os Draconis has effects of suppressing hyperactive liver and subsiding yang, tranquilizing mind and allaying excitement, fructus Lycii has effects of nourishing liver and kidney, replenishing blood and tranquilization, rhizoma Acori Graminei has effects of inducing resuscitation and eliminating phlegm, and refreshing mind and improving intelligence, and is used as adjuvant drug, which is pungent and warm in adjuvant drugs; poria cocos wolf has the functions of invigorating spleen and removing dampness, and calming heart and tranquilizing mind are guiding drugs. The medicines are combined to play the roles of tonifying qi and spleen, nourishing yin and suppressing excessive yang, calming heart and tranquilizing mind, finally balancing yin and yang and coordinating internal organs. Treat both manifestation and root cause of disease and improve various symptoms.
The invention also provides a preparation method of the children ginseng radix astragali poria cocos particles, which comprises the following steps of mixing 15-25 parts by weight of radix codonopsis, 15-25 parts by weight of prepared rehmannia root, 10-20 parts by weight of white peony root, 8-12 parts by weight of schisandra chinensis, 10-20 parts by weight of Chinese yam, 8-12 parts by weight of polygala tenuifolia, 10-20 parts by weight of keel, 8-12 parts by weight of wolfberry fruit, 10-20 parts by weight of rhizoma acori graminei and 10-20 parts by weight of poria cocos, adding 8-13.5 times of water respectively, decocting for 1-3 times for 1-2 hours each time, combining decoction solutions, filtering, concentrating the filtrate at 60 ℃ to thick paste with a relative density of 1.20-1.25 (60 ℃), drying under reduced pressure for 15-20min, crushing into fine powder, and mixing the following extracts: dextrin: mixing sucrose (2-9) and sucrose (1-1.5), granulating, and drying to obtain the final product.
In a preferred embodiment, the raw material medicine consists of the following components in parts by weight: 5 parts of codonopsis pilosula, 5 parts of prepared rehmannia root, 3 parts of white peony root, 2 parts of schisandra chinensis, 3 parts of Chinese yam, 2 parts of polygala tenuifolia, 3 parts of keel, 2 parts of wolfberry fruit, 3 parts of rhizoma acori graminei and 3 parts of poria with hostwood.
In a preferred embodiment, after mixing the raw materials in parts by weight, adding 13.5 times, 12 times and 12 times of water respectively, and decocting for 3 times, each time for 1.5 hours.
In a preferred embodiment, the ratio of extract: dextrin: mixing sucrose (9: 9: 1), and granulating.
The invention also provides application of the children ginseng, radix astragali, poria cocos and lucid ganoderma granules in preparation of medicines for treating attention deficit hyperactivity disorder caused by deficiency of both qi and yin and hyperactivity of yang due to yin deficiency.
The children ginseng-astragalus root poria particle breaks through the traditional treatment thought of tonifying liver and kidney, deeply researches the yin-yang imbalance of the pathogenesis of the traditional Chinese medicine, highlights the traditional Chinese medicine theory of yin-yang constipation and psychology, and has the effects of tonifying qi and yin, and supporting intelligence and calming heart. The invention combines the medicines to play the roles of replenishing qi to invigorate the spleen, nourishing yin to suppress yang, supporting intelligence and calming the heart, finally balancing yin and yang and coordinating internal organs. Treat both manifestation and root cause of disease and improve various symptoms. The traditional Chinese medicine composition has been used clinically for years, and the effective rate of patients with symptom improvement can reach more than 95 percent. The preparation has definite curative effect, no adverse reaction and good safety.
Prescription screening:
the formula is screened in the early stage, different formulas of monarch drug, monarch drug and ministerial drug are screened on the basis of the screening in the early stage, and the dosage of each screened formula is the same as the following formula: 5 parts of codonopsis pilosula, 5 parts of prepared rehmannia root, 3 parts of white peony root, 2 parts of schisandra chinensis, 3 parts of Chinese yam, 2 parts of polygala tenuifolia, 3 parts of keel, 2 parts of wolfberry fruit, 3 parts of rhizoma acori graminei and 3 parts of poria with hostwood, wherein the specific screening formula is as follows:
screening method 1 Screening method 2 Screening method III Screening method Screening method
Codonopsis pilosula Radix pseudostellariae Codonopsis pilosula 0 Codonopsis pilosula
Prepared rehmannia root Prepared rehmannia root 0 Prepared rehmannia root Prepared rehmannia root
White peony root White peony root White peony root White peony root 0
Schisandra chinensis Schisandra chinensis Schisandra chinensis Schisandra chinensis 0
Chinese yam Chinese yam Chinese yam Chinese yam Chinese yam
Root of Polygala Root of Polygala Root of Polygala Root of Polygala Root of Polygala
Keel Keel Keel Keel Keel
Chinese wolfberry Chinese wolfberry Chinese wolfberry Chinese wolfberry Chinese wolfberry
Acorus tatarinowii schott Acorus tatarinowii schott Acorus tatarinowii schott Acorus tatarinowii schott Acorus tatarinowii schott
Poria with pine Poria with pine Poria with pine Poria with pine Poria with pine
The five screening prescriptions are used for pharmacodynamic tests
36 male Spontaneous Hypertensive Rats (SHR) of 4 weeks, 6 Wista Kyoto (WKY) rats were selected, the male SHR rats were randomly divided into 6 groups of 6 rats each, and the same-age WKY rats were set as normal control groups. Decocting the five screening prescriptions in water once, and filtering with a filter cloth to remove impurities. The normal group and the model group were administered with 20ml/kg of physiological saline, and the five screening groups were administered with 21.3g/kg of intragastric administration for 4 consecutive weeks. Before and after 4 weeks of gavage, after fasting for 24h, blood is collected from the orbit, and serum is taken after centrifugation and measured by radioimmunoassay.
Table 1 adrenocorticotropic hormone ACTH levels in serum of rats of each group were determined.
Group of n Before treatment After treatment
Normal group 6 32.47±3.24 31.57±4.56
Model set 6 47.54±4.12 46.32±3.98
Screening method 1 6 47.32±4.54 35.62±3.21
Screening method 2 6 46.76±3.65 38.45±2.83
Screening method III 6 46.84±4.32 41.23±3.47
Screening method 6 47.15±5.02 40.87±3.91
Screening method 6 46.84±4.74 39.32±3.51
There was a decrease in ACTH levels in rats in the post-treatment group, with one of the screening methods being most significant.
Dose screening
According to the best medicine taste selected, different dosages are further selected, and the specific formula is as follows:
TABLE 2 dosage screening
Medicinal composition Dosage 1 Dosage 2 Dosage 3 Dosage 4
Codonopsis pilosula 3 5 7 1
Prepared rehmannia root 3 5 5 1
White peony root 3 3 3 1
Schisandra chinensis 2 2 1 1
Chinese yam 3 3 3 1
Root of Polygala 2 2 3 1
Keel 3 3 2 1
Chinese wolfberry 2 2 3 1
Acorus tatarinowii schott 3 3 6 1
Poria with pine 3 3 3 1
The pharmacodynamic test method and the pharmacodynamic test screened by the prescription determine the ACTH level in the serum of each group of rats.
TABLE 3 measurement of ACTH levels of adrenocorticotropic hormone in serum of rats of each group
Group of n Before treatment After treatment
Normal group 6 32.47±3.24 31.57±4.56
Model set 6 47.54±4.12 46.32±3.98
Dosage 1 6 47.83±5.01 38.63±2.94
Dosage 2 6 47.32±4.54 35.62±3.21
Dosage 3 6 46.63±3.78 39.73±4.13
Dosage 4 6 47.48±4.25 40.21±3.83
There was a decrease in ACTH levels in rats in the post-treatment group, with dose 2 being the most significant.
Designing an extraction process route:
in the prescription, the effective components of the codonopsis pilosula, the prepared rehmannia root, the white paeony root, the Chinese yam, the polygala root, the keel, the Chinese magnoliavine fruit, the medlar, the grassleaf sweelflag rhizome and the poria with hostwood are mostly water-soluble, so the design and extraction process route is as follows: decocting in water.
Water decoction orthogonal experiment
Affecting the extraction effect for water decoctionThere are mainly 3 factors, namely: solvent amount, extraction time, and extraction frequency, using orthogonal Table L9 (3)4) The experiment was arranged, three levels were selected for each factor, and the factors were examined: water addition amount (multiple of medicinal materials), extraction times (times) of B, extraction time (hours) of C and blank of D, and the indexes are examined: the optimal process is selected by taking the extraction rate of verbascoside and the total polysaccharide extraction amount as the investigation indexes. Verbascoside reference (batch No. 2243, Shanghai science and technology (Shanghai) Co., Ltd.), and beta-D glucose reference (batch No. 110833-.
Orthogonal test method: weighing 50g of codonopsis pilosula, 50g of prepared rehmannia root, 30g of white paeony root, 20g of Chinese magnoliavine fruit, 30g of Chinese yam, 20g of polygala root, 30g of dragon bone, 20g of medlar, 30g of grassleaf sweelflag rhizome and 30g of poria with hostwood according to the proportion of a prescription. Decocting in water according to the condition of factor level, filtering, mixing extractive solutions, concentrating under reduced pressure, drying under reduced pressure, and weighing. The method is characterized in that the extraction rate of verbascoside and the total polysaccharide extraction amount are used as investigation indexes, the optimal process is selected, and the water adding amount, the extraction time and the extraction frequency of water extraction are examined. The test results are shown in tables 4 to 7.
TABLE 4 Water extraction factor level table
Figure BDA0003165582720000071
TABLE 5 Water extraction orthogonal test results
Figure BDA0003165582720000072
Figure BDA0003165582720000081
The extraction rate is equal to the content of verbascoside in the extracting solution/the content of verbascoside in the medicinal materials is multiplied by 100
The content of verbascoside is as follows: 0.024 percent
The total polysaccharide extraction amount is polysaccharide content in the extracting solution/medicinal material weight is multiplied by 100
TABLE 6 analysis of variance of acteoside extraction yield
Figure BDA0003165582720000082
Note: f0.05(2,2)=19.0;F0.01(2,2)=99.0
TABLE 7 analysis of variance of total polysaccharide extraction
Figure BDA0003165582720000083
From the orthogonal table visual analysis it follows: when the extraction rate of acteoside is taken as an evaluation index, the influence sequence of all factors on the experimental result is C > A > B, and the three factors A, B, C have no significant influence. The optimal extraction conditions are A2B3C 3; when the total polysaccharide extraction amount is taken as an evaluation index, the influence sequence of all factors on the experimental result is C > A > B, wherein the influence of the C extraction frequency on the result is more obvious. The optimal extraction conditions were A3B1C 3. Because the two indexes have different preferable results, the weight is used for further optimization selection, and the weight coefficients are distributed evenly.
The weight score is the maximum acteoside extraction rate/extraction rate of each group x 50+ total polysaccharide extraction/total polysaccharide extraction of each group x 50.
And performing orthogonal analysis on the weighting results, and selecting the optimal process, wherein the results are shown in tables 8 to 9.
Table 8 water extraction weighted quadrature results
Figure BDA0003165582720000091
TABLE 9 weighted result ANOVA Table
Figure BDA0003165582720000101
The influence sequence of each factor on the experimental result is C obtained from the visual analysis of the orthogonal table>B>A, optimal extractionWith the proviso that A2B3C3. I.e. 12 times the amount of water, 1.5 hours each time, 3 times.
To verify the rationality of the preferred extraction process conditions, according to A2B3C3The process, namely 12 times of water, each time for 1.5 hours, was carried out for three separate runs of verification, with 3 extractions, and the results are given in table 10 below.
TABLE 10 verification results
Figure BDA0003165582720000102
As can be seen from the above table, the average extraction rate of verbascoside is 82.31%, the extraction amount of total polysaccharide is 40.72g/100g, the maximum extraction rate of verbascoside in orthogonal test is 81.80%, and the maximum extraction amount of total polysaccharide is 43.73g/100g, so the extraction process is feasible.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
Example 1
5 parts of codonopsis pilosula, 5 parts of prepared rehmannia root, 3 parts of white peony root, 2 parts of schisandra chinensis, 3 parts of Chinese yam, 2 parts of polygala tenuifolia, 3 parts of keel, 2 parts of wolfberry fruit, 3 parts of rhizoma acori graminei and 3 parts of poria with hostwood.
Mixing the raw materials according to the parts by weight, adding 13.5 times, 12 times and 12 times of water respectively, decocting for 3 times, each time for 1.5 hours, mixing the decoctions, filtering, concentrating the filtrate at 60 ℃ to obtain thick paste with the relative density of 1.20(60 ℃), drying under reduced pressure, pulverizing into fine powder according to the weight ratio of the extract: dextrin: and (3) uniformly mixing the sucrose (9: 9: 1), granulating, and drying to obtain the pediatric ginseng, rhizoma polygonati and poria cocos granules.
Example 2
3 parts of codonopsis pilosula, 3 parts of prepared rehmannia root, 3 parts of white peony root, 2 parts of schisandra chinensis, 3 parts of Chinese yam, 2 parts of polygala tenuifolia, 3 parts of keel, 2 parts of wolfberry fruit, 3 parts of rhizoma acori graminei and 3 parts of poria with hostwood.
Mixing the raw materials according to the parts by weight, adding 13 times, 12 times and 10 times of water respectively, decocting for 3 times, each time for 1.5 hours, mixing the decoctions, filtering, concentrating the filtrate at 60 ℃ to obtain thick paste with the relative density of 1.25(60 ℃), drying under reduced pressure, pulverizing into fine powder according to the weight ratio of the extract: dextrin: and (3) uniformly mixing the sucrose (9: 9: 1), granulating, and drying to obtain the pediatric ginseng, rhizoma polygonati and poria cocos granules.
Pharmacodynamic test
30 male Spontaneous Hypertensive Rats (SHR) at 4 weeks, 6 Wista Kyoto (WKY) rats were selected, the male SHR rats were randomly divided into 5 groups of 6 rats each, and the same-age WKY rats were set as a normal control group. The normal group and the model group are administrated with 20ml/kg of physiological saline, the positive control group is administrated with 5.24mg/kg of atomoxetine hydrochloride for intragastric administration, and the high, medium and low dose groups of the pediatric Shenhuang Fuzhi granule example 1 are administrated with 5.325g/kg, 10.65g/kg and 21.3g/kg for intragastric administration respectively for 6 weeks. Before and after 6 weeks of gavage, after fasting for 24h, blood is collected from the orbit, serum is taken after centrifugation, and the specific measurement results are determined by a radioimmunoassay and are shown in the table below.
TABLE 11 measurement of ACTH levels in serum of rats of each group
Figure BDA0003165582720000111
Figure BDA0003165582720000121
The ACTH water level of rats in the post-treatment administration group is reduced, wherein the ACTH level in the serum of the pediatric ginseng radix astragali poria cocos particle group prepared by screening the extraction process conditions is obviously reduced compared with that of the pediatric ginseng radix astragali poria cocos particle group extracted by one-time water decoction of the previous screening formula.
TABLE 12 determination of Cortisol levels in serum of rats in each group
Group of n Before treatment After treatment
Normal group 6 289.53±63.32 363.42±42.73
Model set 6 273.32±73.21 294.31±68.32
Positive control group 6 264.32±53.21 346.73±58.32
High dose group 6 257.82±61.45 339.56±63.09
Middle dose group 6 268.54±57.52 321.45±58.54
Low dose group 6 251.56±72.76 316.73±71.98
After treatment, other groups are lower than normal groups, the administration group has the tendency of improving the cortisol level in the serum of rats, and the pediatric Shenhuang Fuzhuan granule high-dose group and the positive control group have the obvious effect of improving the cortisol level in the serum of model rats.
Clinical data
The Shenhuang Fuzhuan granule for children is the agreement prescription of the first hospital of Jilin university. Incomplete statistics shows that more than 1000 patients in medical department of traditional Chinese medicine in the hospital use the formula, and many patients actively require to take the formula, so that the curative effect is exact and no side effect is caused. The prescription is based on replenishing qi to invigorate the spleen, nourishing yin to suppress yang, strengthening intelligence and calming the heart, enhancing attention and improving cognitive function, and 10 traditional Chinese medicines are selected: radix codonopsitis, prepared rehmannia root, white paeony root, Chinese magnoliavine fruit, Chinese yam, polygala root, keel, medlar, grassleaf sweelflag rhizome and poria with hostwood. The latest component compatibility theory of the traditional Chinese medicine is taken as guidance to form the traditional Chinese medicine compound preparation.
100 patients were randomly selected from the Guilin university first Hospital 2015-2019.
The patient uses the crowd: the traditional Chinese medicine differentiation of attention deficiency hyperactivity disorder of children belongs to the syndrome of deficiency of both qi and yin deficiency and yang hyperactivity. The symptoms are as follows: restlessness, distraction, urgency, irritability, multilingual, night sweats, dry mouth and tongue, feverish palms and soles.
The usage and dosage are as follows: example 1, oral administration, 6-9 years old, 1 bag at a time, 2 times a day. It is administered by 2 bags 2 times a day over 10 years old. It is administered with warm boiled water.
Through retrospective analysis of clinical cases, the prescription preparation is safe and effective and definitely receives the welcome and favorable comment of patients. The trend analysis is carried out on the reference standard of clinical cure or improvement or the relevant indexes of the traditional Chinese medicine curative effect standard, the total effective rate is 95 percent, the symptom is obviously improved by 87 percent, the symptom is improved by 5 percent, the rate of return diagnosis is 100 percent, and the average course of treatment is 7 days. Typical cases are exemplified as follows.
Typical case 1
Name: after a certain period of time
Sex: woman
Age: 11
The main complaints are: restlessness, feverish palms and soles, night sweats, inattention, frequent loss of the east and west, and excessive speech.
History of the past: none.
Physical examination: pale tongue with thin and white coating, weak pulse, body temperature of 36.0 deg.C, and height of 132 cm.
And (3) diagnosis: attention deficit and hyperactivity disorder due to deficiency of both qi and yin and hyperactivity of yang due to yin deficiency.
Treatment: replenishing qi to invigorate the spleen, nourishing yin to suppress yang, calming the heart and tranquilizing the mind, taking the children's ginseng, radix astragali and poria cocos particles, and rechecking 7 days later.
And (3) return diagnosis: the symptoms of restlessness, feverish palms and soles and night sweat are relieved, and the medicine is continuously taken for a re-diagnosis after 7 days.
Typical case 2
Name: cai a
Sex: for male
Age: 9
The main complaints are: restlessness, inattention, urgency, irritability, decline of learning performance, running disorder, and restlessness.
History of the past: none.
Physical examination: the tongue is pale with white coating, the pulse is thin, the body temperature is 36.5 ℃, and the height is 125 cm.
And (3) diagnosis: attention deficit and hyperactivity disorder caused by deficiency of both qi and yin and hyperactivity of yang due to yin deficiency.
Treatment: replenishing qi to invigorate the spleen, nourishing yin to suppress yang, calming the heart and tranquilizing the mind, taking the children's ginseng, radix astragali and poria cocos particles, and rechecking 7 days later.
And (3) return diagnosis: the restlessness symptom is relieved, the medicine is continuously taken, and the patient is subjected to the double-diagnosis after 7 days.
Typical case 3
Name: cao somewhere
Sex: woman
Age: 7
The main complaints are: restlessness, manual operation, interference to others and excessive speech.
History of the past: none.
Physical examination: pale tongue with white coating, thready and rapid pulse, body temperature of 36.0 deg.C, and height of 126 cm.
And (3) diagnosis: attention deficit and hyperactivity disorder caused by deficiency of both qi and yin and hyperactivity of yang due to yin deficiency.
Treatment: replenishing qi to invigorate the spleen, nourishing yin to suppress yang, calming the heart and tranquilizing the mind, taking the children's ginseng, radix astragali and poria cocos particles, and rechecking 7 days later.
And (3) return diagnosis: the patient is restless, manually operates the feet, often interferes with other people to relieve the symptoms, continues to take the medicine, and makes a double-diagnosis after 7 days.
While certain exemplary embodiments of the present invention have been described above by way of illustration only, it will be apparent to those of ordinary skill in the art that the described embodiments may be modified in various different ways without departing from the spirit and scope of the invention. Accordingly, the foregoing description is illustrative in nature and is not to be construed as limiting the scope of the invention as claimed.

Claims (2)

1. The children ginseng-radix astragali-poria cocos particle for treating attention deficit hyperactivity disorder is characterized by being prepared from the following raw material medicines in parts by weight: 5 parts of codonopsis pilosula, 5 parts of prepared rehmannia root, 3 parts of white peony root, 2 parts of schisandra chinensis, 3 parts of Chinese yam, 2 parts of polygala tenuifolia, 3 parts of keel, 2 parts of wolfberry fruit, 3 parts of rhizoma acori graminei and 3 parts of poria with hostwood; the preparation method of the children ginseng, radix astragali, poria cocos and poria cocos particle comprises the following steps: mixing the raw materials in parts by weight, adding 12 times of water respectively, decocting for 3 times, each time for 1.5 hours, mixing decoctions, filtering, concentrating the filtrate at 60 ℃ to obtain a thick paste with a relative density of 1.20-1.25, drying under reduced pressure for 15-20min, pulverizing into fine powder, and mixing the fine powder: dextrin: and (3) uniformly mixing sucrose =9:9:1, granulating, and drying to obtain the product.
2. The pediatric ginseng huang fu zhi ke li of claim 1, for use in the preparation of a medicament for the treatment of attention deficit hyperactivity disorder.
CN202110803847.3A 2021-07-16 2021-07-16 Children ginseng-radix astragali-poria cocos particle as well as preparation method and application thereof Active CN113318174B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110803847.3A CN113318174B (en) 2021-07-16 2021-07-16 Children ginseng-radix astragali-poria cocos particle as well as preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110803847.3A CN113318174B (en) 2021-07-16 2021-07-16 Children ginseng-radix astragali-poria cocos particle as well as preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN113318174A CN113318174A (en) 2021-08-31
CN113318174B true CN113318174B (en) 2022-04-22

Family

ID=77426380

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110803847.3A Active CN113318174B (en) 2021-07-16 2021-07-16 Children ginseng-radix astragali-poria cocos particle as well as preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN113318174B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104873687B (en) * 2015-06-04 2019-09-13 王俊宏 A kind of Chinese medicine composition for treating the mostly dynamic obstacle of child attention defect

Also Published As

Publication number Publication date
CN113318174A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
CN101332284B (en) Chinese traditional medicine composition for treating ulcerative colitis and its preparation method
CN100546615C (en) Be used for the treatment of Chinese medicine composition of cerebrovascular and preparation method thereof
CN101982193B (en) Traditional Chinese medicine composition for treating pulmonary tuberculosis, preparation method and application thereof
CN113318174B (en) Children ginseng-radix astragali-poria cocos particle as well as preparation method and application thereof
CN112336802B (en) Traditional Chinese medicine composition for improving glycolipidosis metabolism of diabetes and application thereof
CN101411493B (en) Cold tea for preventing and treating fatigue type sub-health and preparation method thereof
CN113599447A (en) Traditional Chinese medicine composition for improving phlegm-dampness constitution and preparation method and application thereof
CN100372557C (en) Oral liquid capable of raising human body anoxia tolerance and its preparation method
CN101020026B (en) Honeyed Guiqi ointment for enhancing body's resistance and its preparation
CN105561097B (en) It is a kind of to treat Chinese medicine composition lungy and preparation method thereof
CN104587300A (en) Traditional Chinese medicine composition for treating acute leukemia and preparation method of traditional Chinese medicine composition
AU2021101743A4 (en) Preparation Method of Polygonatum sibiricum Tea Bag Combined with Exercise for Prevention and Adjuvant Therapy for Hyperglycemia
CN113616742B (en) Traditional Chinese medicine composition for treating lung and spleen deficiency of pulmonary diseases and preparation method and application thereof
CN112043757B (en) Health-preserving coffee and traditional Chinese medicine composition
CN116850224B (en) Traditional Chinese medicine composition for preventing and treating epidemic disease and preparation method thereof
CN103751415B (en) Traditional Chinese medicinal composition and preparation method thereof
CN102973817A (en) Compound traditional Chinese medicine preparation for treating atherosclerosis, and preparation method thereof
CN105941773A (en) Health care tea and application thereof
CN107137557B (en) Chinese medicinal compound preparation for treating anemia caused by deficiency of vital energy and essence and preparation method thereof
CN107007721B (en) Traditional Chinese medicine compound preparation for treating anemia caused by qi deficiency of spleen and kidney and preparation method
CN105853582A (en) Folium artemisiae argyi containing medicine preparation for treating cholelithiasis and preparation method thereof
CN105838560A (en) Folium Artemisiae Argyi healthcare wine and making method thereof
CN107753638B (en) Medicine for promoting bone marrow hematopoiesis and preparation method and application thereof
CN113577252A (en) Chinese medicinal preparation for regulating blood fat and preparation method thereof
CN117244016A (en) Traditional Chinese medicine composition for preventing and treating cancer-induced fatigue and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220824

Address after: Room 203, unit 1, building 42, Wenting Yayuan, Chaoyang District, Changchun City, Jilin Province, 130000

Patentee after: Jilin Huanyu Jimin Technology Co.,Ltd.

Address before: 133700 room 206-0001001, Xiashi Industrial Park, Dunhua, Yanbian Korean Autonomous Prefecture, Jilin Province

Patentee before: Jilin Huanyu Jimin Pharmaceutical Co.,Ltd.

TR01 Transfer of patent right